RNA compound reduced abnormal blood vessel lesions in mice
A single injection into the eye reduced lesion volume in a laser-induced mouse model of abnormal blood vessel growth.
Our read
Interventions- Studied:
- Experiments in mice with laser-induced abnormal blood vessel growth
- What changed:
- Mice given OLX10212 had smaller abnormal blood vessel lesions after a single injection into the eye
- The catch:
- Vision outcomes were not reported for the abnormal blood vessel growth experiments
- Stake:
- Authors work for Olix Pharmaceuticals, which develops olx10212, hold shares in it, or both.
Editor of record: Boris Djordjevic · AgingResearch.News
Mice and cynomolgus monkeys given a single injection of OLX10212 into the eye had smaller lesions in experiments that used lasers to trigger abnormal blood vessel growth. The experimental RNA compound was designed to reduce production of MyD88, a protein that relays immune signals. After injection in mice and rabbits, it spread widely through the retina, the light-sensing tissue at the back of the eye, and produced sustained suppression of MyD88.
In two induced models of retinal degeneration, the compound preserved tissue structure and electrical responses to light. It also reduced activity of genes associated with inflammatory signaling. Applied to the eye surface, it reduced injury to the cornea, the clear front of the eye, and production of inflammatory signals in a chemically induced dry eye model.
Why it matters
Chronic inflammation contributes to age-related macular degeneration. These experiments explored whether silencing an immune-signaling protein could address several forms of inflammation-related eye damage.
Caveats
The reported benefits came from experimentally induced eye disease in animals, not outcomes in patients. A phase 1 trial in patients with age-related macular degeneration involving abnormal blood vessel growth was ongoing.
The paper
Inc.; Sungkyunkwan University
Molecular Therapy, Jun 26, 2026, Open access
Comments
Be the first to comment.